Oculis Holding Ag (OCS)

$28.65 -0.52 (-1.78%)
Market Cap 1.53B
Revenue (ttm) 780,000.00
Net Income (ttm) -97.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -12,491.03%
Debt to Equity Ratio 0.00
Volume 529,600
Avg Vol 250,266
Day's Range N/A - N/A
Shares Out 52.38M
Stochastic %K 61%
Beta 0.28
Analysts Strong Sell
Price Target $44.51

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective a...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 711 3960
Website: oculis.com
Address:
Bahnhofstrasse 20, Zug, Switzerland
Champi2305
Champi2305 Feb. 19 at 8:05 PM
$OCS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 12:00 AM
$OCS RSI: 56.97, MACD: 1.4193 Vol: 0.97, MA20: 27.84, MA50: 23.79 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
justiceforb_85
justiceforb_85 Feb. 17 at 4:58 AM
$OCS very much under-the-radar. Could see this doubling with positive OCS-01 data at the least.
0 · Reply
Champi2305
Champi2305 Feb. 13 at 6:31 PM
$OCS $SPY I told you ! Amazing pipeline Amazing CEO More and more volume
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 9 at 10:48 PM
$OCS Current Stock Price: $28.35
0 · Reply
Microstructure
Microstructure Feb. 4 at 1:50 PM
$OCS is a provider of outsourced customer engagement services; demand is stable but the business is competitive and sensitive to wage inflation.
0 · Reply
Champi2305
Champi2305 Jan. 30 at 6:22 PM
$OCS Always Green
0 · Reply
Social_Idiot
Social_Idiot Jan. 28 at 4:10 PM
$OCS beast mode unlocked
0 · Reply
Champi2305
Champi2305 Jan. 28 at 9:55 AM
$OCS
0 · Reply
Social_Idiot
Social_Idiot Jan. 22 at 11:58 PM
$OCS AI is showing some cooling off. It's a low rated buy. Potentially turning into an exhaustion gap or reversal.
0 · Reply
Latest News on OCS
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Feb 18, 2026, 4:05 PM EST - 5 days ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Oculis Appoints Katie Kazem as Chief Legal Officer

Feb 17, 2026, 4:00 AM EST - 6 days ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Oculis Holding AG (OCS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 16, 2026, 12:26 PM EST - 5 weeks ago

Oculis Holding AG (OCS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:00 AM EST - 6 weeks ago

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Jan 6, 2026, 4:00 AM EST - 6 weeks ago

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Dec 9, 2025, 4:05 PM EST - 2 months ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Nov 10, 2025, 4:05 PM EST - 3 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Oculis to Participate in Upcoming November Investor Conferences

Nov 5, 2025, 4:00 AM EST - 3 months ago

Oculis to Participate in Upcoming November Investor Conferences

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oct 30, 2025, 4:30 AM EDT - 4 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oct 14, 2025, 4:00 AM EDT - 4 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Oct 6, 2025, 4:07 AM EDT - 5 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Sep 26, 2025, 4:05 PM EDT - 5 months ago

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Sep 22, 2025, 4:00 AM EDT - 5 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Sep 4, 2025, 1:00 PM EDT - 6 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Sep 1, 2025, 4:00 AM EDT - 6 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Oculis to Participate in Upcoming September Investor Conferences

Aug 28, 2025, 4:00 AM EDT - 6 months ago

Oculis to Participate in Upcoming September Investor Conferences

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Aug 25, 2025, 4:00 AM EDT - 6 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Aug 21, 2025, 4:05 PM EDT - 6 months ago

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 7 months ago

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 7 months ago

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Oculis Upsized Loan Facility to Access up to CHF 100 million

Aug 1, 2025, 4:00 AM EDT - 7 months ago

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Publishes Results of 2025 Annual General Meeting

Jun 5, 2025, 4:00 AM EDT - 9 months ago

Oculis Publishes Results of 2025 Annual General Meeting

Oculis to Participate in Upcoming June Investor Conferences

Jun 3, 2025, 4:00 AM EDT - 9 months ago

Oculis to Participate in Upcoming June Investor Conferences

Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025, 4:05 PM EDT - 10 months ago

Oculis Publishes Invitation to the Annual General Meeting

Oculis Reports Q1 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 10 months ago

Oculis Reports Q1 Financial Results and Provides Company Update

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 8, 2025, 4:05 PM EDT - 10 months ago

Oculis Reports Q1 2025 Financial Results and Provides Company Update

Oculis to Present at Upcoming May Investor Conferences

May 7, 2025, 4:00 AM EDT - 10 months ago

Oculis to Present at Upcoming May Investor Conferences

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

May 1, 2025, 4:00 AM EDT - 10 months ago

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

May 1, 2025, 4:00 AM EDT - 10 months ago

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Oculis Updates Share Capital

Apr 25, 2025, 4:00 PM EDT - 10 months ago

Oculis Updates Share Capital

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Apr 17, 2025, 5:00 AM EDT - 11 months ago

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Apr 15, 2025, 4:00 AM EDT - 11 months ago

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Apr 10, 2025, 8:00 AM EDT - 11 months ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Apr 10, 2025, 4:00 AM EDT - 11 months ago

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Apr 1, 2025, 4:00 AM EDT - 11 months ago

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Mar 20, 2025, 6:01 PM EDT - 1 year ago

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Oculis to Present at Upcoming March Investor Conference

Mar 5, 2025, 4:00 AM EST - 1 year ago

Oculis to Present at Upcoming March Investor Conference

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Feb 13, 2025, 7:40 PM EST - 1 year ago

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Oculis updates share capital for its existing at-the-market offering program

Jan 31, 2025, 4:00 PM EST - 1 year ago

Oculis updates share capital for its existing at-the-market offering program

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Jan 21, 2025, 8:00 AM EST - 1 year ago

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Jan 6, 2025, 3:53 AM EST - 1 year ago

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

Nov 27, 2024, 4:15 AM EST - 1 year ago

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

Oculis to Present at the Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:00 AM EST - 1 year ago

Oculis to Present at the Stifel 2024 Healthcare Conference

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Nov 7, 2024, 4:00 AM EST - 1 year ago

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Oct 21, 2024, 1:04 PM EDT - 1 year ago

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Oct 15, 2024, 4:00 AM EDT - 1 year ago

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ONCO VRNA GRDX

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Oct 2, 2024, 4:00 AM EDT - 1 year ago

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Sep 19, 2024, 1:00 PM EDT - 1 year ago

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Champi2305
Champi2305 Feb. 19 at 8:05 PM
$OCS
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 12:00 AM
$OCS RSI: 56.97, MACD: 1.4193 Vol: 0.97, MA20: 27.84, MA50: 23.79 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
justiceforb_85
justiceforb_85 Feb. 17 at 4:58 AM
$OCS very much under-the-radar. Could see this doubling with positive OCS-01 data at the least.
0 · Reply
Champi2305
Champi2305 Feb. 13 at 6:31 PM
$OCS $SPY I told you ! Amazing pipeline Amazing CEO More and more volume
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 9 at 10:48 PM
$OCS Current Stock Price: $28.35
0 · Reply
Microstructure
Microstructure Feb. 4 at 1:50 PM
$OCS is a provider of outsourced customer engagement services; demand is stable but the business is competitive and sensitive to wage inflation.
0 · Reply
Champi2305
Champi2305 Jan. 30 at 6:22 PM
$OCS Always Green
0 · Reply
Social_Idiot
Social_Idiot Jan. 28 at 4:10 PM
$OCS beast mode unlocked
0 · Reply
Champi2305
Champi2305 Jan. 28 at 9:55 AM
$OCS
0 · Reply
Social_Idiot
Social_Idiot Jan. 22 at 11:58 PM
$OCS AI is showing some cooling off. It's a low rated buy. Potentially turning into an exhaustion gap or reversal.
0 · Reply
Social_Idiot
Social_Idiot Jan. 20 at 9:54 PM
$OCS My AI still saying buy.
0 · Reply
Champi2305
Champi2305 Jan. 17 at 11:58 AM
$OCS Volume increasing. 1st target at $28. I keep this stock till $200. A buyout is obvious in the 2 or 3 next years when Oculis will demonstrate the huge potential in MS relapse.
0 · Reply
Social_Idiot
Social_Idiot Jan. 16 at 10:35 PM
$OCS My AI still saying it's a buy.
0 · Reply
Champi2305
Champi2305 Jan. 16 at 8:16 PM
$OCS This is a just the beginning.
0 · Reply
Champi2305
Champi2305 Jan. 16 at 11:46 AM
$OCS https://investors.oculis.com/static-files/f33f41c2-2c60-4985-a6db-c42b1f8fb477
0 · Reply
Champi2305
Champi2305 Jan. 16 at 11:44 AM
$OCS https://www.neurologylive.com/view/neuroprotective-agent-privosegtor-gains-fda-breakthrough-designation-optic-neuritis
0 · Reply
Champi2305
Champi2305 Jan. 15 at 6:37 PM
$OCUL $OCS will be the next one. amazing pipeline.
0 · Reply
Champi2305
Champi2305 Jan. 14 at 10:18 PM
$OCS great JPM healthcare webconf. Amazing potential. Incredible phases 2 results. Oculis has a ton of cash . Great ceo. Future looks good.
0 · Reply
justiceforb_85
justiceforb_85 Jan. 14 at 7:13 PM
$OCS added. Like the potential on this one, mainly for privosegtor in ON/NAION.
1 · Reply
Champi2305
Champi2305 Jan. 12 at 9:04 PM
$SPY $OCS last call !
0 · Reply
Champi2305
Champi2305 Jan. 9 at 5:33 PM
$OCS $PGEN $SLS $TEVA $NVO
0 · Reply
TipRanks
TipRanks Jan. 8 at 11:08 AM
J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks https://www.tipranks.com/news/article/j-p-morgan-bangs-the-drum-on-these-2-strong-buy-stocks $OCS $GTX
0 · Reply